Clinigen Group plc AGM Statement (9093O)

TIDMCLIN

RNS Number : 9093O

Clinigen Group plc

11 November 2016

11 November 2016

AGM statement

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, is holding its Annual General Meeting ("AGM") at 10.00am today.

At the AGM, Peter Allen, Clinigen's Chairman will say:

"The year to 30 June 2016 marked the completion of our transformation into the global market leader in the management and supply of both unlicensed and clinical trial medicines.

"Alongside significant strategic progress, we delivered a strong financial performance with good levels of organic growth combining with acquisitions to increase adjusted EPS* by 25%. Trading for the current financial year remains in line with the Board's expectations.

"At the management level, as you know, Peter George will step down as CEO after the AGM and Shaun Chilton will now take over. We are pleased Peter will continue to work with the Group as a Non-Executive Director.

"Our focus is now fixed on leveraging our global leadership positions, and we will continue to drive organic growth supported by acquisitions and the revitalisation of products."

*Adjusted basic earnings per share is excluding share based payment costs, non-underlying costs, amortisation and associated tax credit.

- Ends-

 
 Clinigen Group plc                  Tel: [phone] 
                                      495 010 
 Shaun Chilton, Group Chief 
  Executive Officer-designate 
  Martin Abell, Group Chief 
  Financial Officer 
 Matt Parrish, Head of Investor 
  Relations 
 
 Numis Securities Limited            Tel: [phone] 
                                      1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 Peel Hunt LLP                       Tel: [phone] 
                                      8900 
 James Steel / Dr Christopher 
  Golden 
 
 Instinctif Partners (media          Tel: [phone] 
  relations)                          2020 
 Melanie Toyne-Sewell / Jayne 
  Crook / Emma Barlow                Email: [e-mail] 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.

The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.

The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions:

Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).

Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.

For more information, please visit www.clinigengroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGMURUVRNSAAAAA

(END) Dow Jones Newswires

November 11, 2016 02:00 ET (07:00 GMT)